Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-9, 2012, Belo Horizonte, Minas Gerais, Brazil
详细信息 查看全文
- 作者：Renato D. Lopes (1) (2)
Richard C. Becker (1)
L. Kristin Newby (1)
Eric D. Peterson (1)
Elaine M. Hylek (3)
Robert Giugliano (4)
Christopher B. Granger (1)
Kenneth W. Mahaffey (1)
Antonio C. Carvalho (2)
Otavio Berwanger (5)
Roberto R. Giraldez (6)
Gilson Soares Feitosa-Filho (7)
Marcia M. Barbosa (8)
Maria da Consolacao V. Moreira (9)
Renato A. K. Kalil (10)
Marildes Freitas (11)
Joao Carlos de Campos Guerra (12)
Marcio Vinicius Lins Barros (13)
Thiago da Rocha Rodrigues (14)
Antonio C. Lopes (2)
David A. Garcia (15) - 关键词：Thrombosis ; Antithrombotic therapy ; Guidelines ; Clinical research
- 刊名：Journal of Thrombosis and Thrombolysis
- 出版年：2013
- 出版时间：July 2013
- 年：2013
- 卷：36
- 期：1
- 页码：115-130
- 全文大小：271KB
- 参考文献：1. ACTIVE Writing Group (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 367:1903-912 CrossRef
2. Adams HP Jr, del Zoppo G, Alberts MJ et al (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke 38:1655-711 CrossRef
3. Ainsworth CD, Blake CC, Tamayo A et al (2005) 3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies. Stroke 36:1904-909 CrossRef
4. Alexander KP, Chen AY, Roe MT et al (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108-116 CrossRef
5. Alexander KP, Peterson ED (2010) Minimizing the risks of anticoagulants and platelet inhibitors. Circulation 121:1960-970 CrossRef
6. Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 50:e1–e157 CrossRef
7. Avgil Tsadok M (2012) Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 307:1952-958 CrossRef
8. Bailey AL, Scantlebury DC, Smyth SS (2009) Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol 29:284-88 CrossRef
9. Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8:2450-457 CrossRef
10. Berwanger O, Guimar?es HP, Laranjeira LN et al (2012) Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial. JAMA 307:2041-049 CrossRef
11. Boersma E, Harrington RA, Moliterno DJ et al (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359:189-98 CrossRef
12. Bonow RO, Carabello BA, Chatterjee K et al (2008) 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118:e523–e661 CrossRef
13. Brennan JM, Edwards FH, Zhao Y et al (2012) Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 60:971-77 CrossRef
14. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 23:2369-429
15. Capodanno D, Angiolillo DJ (2010) Impact of race and gender on antithrombotic therapy. Thromb Haemost 104:471-84 CrossRef
16. Chan MY, Sun JL, Wang TY et al (2010) Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J 160:1056-064 CrossRef
17. Cohen M, Demers C, Gurfinkel EP et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337:447-52 CrossRef
18. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-435 CrossRef
19. Cooper HA, Rao SV, Greenberg MD et al (2011) Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol 108:1108-111 CrossRef
20. Costa GL, Ferreira DC, Valacio RA, Vieira Moreira Mda C (2011) Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: a prospective cohort study. Age Ageing 40:375-81 CrossRef
21. Ducharme A, Swedberg K, Pfeffer MA et al (2006) Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 151:985-91 CrossRef
22. Eikelboom JW, Wallentin L, Connolly SJ et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation 123:2363-372 CrossRef
23. Ensor CR, Cahoon WD, Crouch MA et al (2010) Antithrombotic therapy for the CardioWest temporary total artificial heart. Texas Heart Inst J 37:149-58
24. Ezekowitz MD, Wallentin L, Connolly SJ et al (2010) Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 122:2246-253 CrossRef
25. Feinstein SB (2006) Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. J Am Coll Cardiol 48:236-43 CrossRef
26. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464-476 CrossRef
27. Fox KAA, Piccini JP, Wojdyla D et al (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32:2387-394 CrossRef
28. Furie KL, Goldistein LB, Albers GW et al (2012) Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43:3442-453 CrossRef
29. Furie KL, Kasner SE, Adams RJ et al (2011) Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:227-76 CrossRef
30. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864-870 CrossRef
31. Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167-177 CrossRef
32. Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-92 CrossRef
33. Gualandro DM, Yu PC, Calderaro D et al (2011) II guidelines for perioperative evaluation. Arq Bras Cardiol 96(3 Suppl 1):1
34. Healey JS, Connolly SJ, Gold MR et al (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120-29 CrossRef
35. Hijazi Z, Oldgren J, Andersson U et al (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 125:1605-616 CrossRef
36. Hohnloser SH, Hijazi Z, Thomas L et al (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33:2821-830 CrossRef
37. Homma S, Thompson JL, Pullicino PM et al (2012) Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 366:1859-869 CrossRef
38. Khan IA (2003) Atrial stunning: basics and clinical consideration. Int J Cardiol 2003(92):113-28 CrossRef
39. Klein AL, Grimm RA, Murray RD et al (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344:1411-420 CrossRef
40. Lazar RM, Shapiro PA, Jaski BE et al (2004) Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation 109:2423-427 CrossRef
41. Leiria TL, Pellanda L, Miglioranza MH et al (2010) Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic. Arq Bras Cardiol 94:40-3 CrossRef
42. Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597-607 CrossRef
43. Lindqvist PG, Epstein E, Olsson H (2008) The relationship between lifestyle factors and venous thromboembolism among women: a report from the MISS study. Br J Haematol 144:234-40 CrossRef
44. Lip GYH, Ponikowski P, Andreotti F et al (2012) Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 14:681-95 CrossRef
45. Little SH, Massel DR (2003) Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 4:CD003464
46. Lopes RD, Peterson ED, Chen AY et al (2010) Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. J Am Coll Cardiol Intv 3:669-77
47. Lopes RD, Subherwal S, Holmes DN et al (2012) The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. Eur Heart J 33:2044-053 CrossRef
48. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness—a systematic review and meta-analysis. Circulation 115:459-67 CrossRef
49. Lorenz MW, Polak JF, Kavousi M et al (2012) Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 379:2053-062 CrossRef
50. Lubenow N, Hinz P, Thomaschewski S et al (2010) The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 115:1797-803 CrossRef
51. Maggioni A, Latini R, Carson PE et al (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149:548-57 CrossRef
52. Mehran R, Pocock SJ, Nikolsky E et al (2010) A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 55:2556-566 CrossRef
53. Mehran R, Pocock SJ, Stone GW et al (2009) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30:1457-466 CrossRef
54. Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736-747 CrossRef
55. Mehta SK, Frutkin AD, Lindsey JB et al (2009) Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Intv 2:222-29 CrossRef
56. Miedema I, Luijckx GJ, De Keyser J, Koch M, Uyttenboogaart M (2012) Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 83:537-40 CrossRef
57. Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404-413 CrossRef
58. Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC (2012) Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of Get With The Guidelines-Heart Failure. Circ Heart Fail 5:191-01 CrossRef
59. Olesen J, Lip GY, Hansen ML et al (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342:d124 CrossRef
60. Olsson SG, Swedberg K, Ducharme A et al (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47:1997-004 CrossRef
61. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-91 CrossRef
62. Petersen JL, Mahaffey KW, Hasselblad V et al (2004) Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 29289-9296
63. Potapov EV, Krabatsch T, Ventura HO, Hetzer R (2011) Advances in mechanical circulatory support: year in review. J Heart Lung Transplant 30:487-93 CrossRef
64. Price J, Hynes M, Labinaz M, Ruel M, Boodhwani M (2012) Mechanical valve thrombosis with dabigatran. J Am Coll Cardiol 60:1710-711 CrossRef
65. The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339:436-43 CrossRef
66. Rao SV, Eikelboom J, Steg PG et al (2009) Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J 158(881-86):e1
67. Rao SV, Jollis JG, Harrington RA et al (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292:1555-562 CrossRef
68. Rao SV, Kaul PR, Liao L et al (2008) Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 155:369-74 CrossRef
69. Rao SV, O’Grady K, Pieper KS et al (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200-206 CrossRef
70. Rao SV, O’Grady K, Pieper KS et al (2006) A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47:809-16 CrossRef
71. Rossi M, Serraino GF, Jiritano F, Renzulli A (2012) What is the optimal anticoagulation in patients with a left ventricular assist device? Interact Cardiovasc Thorac Surg 15:733-40 CrossRef
72. Roy D, Talajic M, Nattel S et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667-677 CrossRef
73. Roy P, Bonello L, Torguson R et al (2008) Impact of “nuisance-bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 102:1614-617 CrossRef
74. Scirica BM, Bonaca MP, Braunwald E et al (2012) Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 380:1317-324 CrossRef
75. Shantsila E, Lip GY, Chong BH (2009) Heparin-induced thrombocytopenia: a contemporary clinical approach to diagnosis and management. Chest 135:1651-664 CrossRef
76. Shibazaki K, Kimura K, Fujii S, Sakai K, Iguchi Y (2012) Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol 109:1303-307 CrossRef
77. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-91 CrossRef
78. Spyropoulos AC, Anderson FA Jr, Fitzgerald G et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706-14 CrossRef
79. Stein JH, Korcarz CE, Hurst RT et al (2008) Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 21:93-11 CrossRef
80. Stein PD, Henry JW (1995) Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 108:978-81 CrossRef
81. Subherwal S, Bach RG, Chen AY et al (2009) Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 119:1873-882 CrossRef
82. Suissa L, Bresch S, Lachaud S, Mahagne MH (2012) Brain natriuretic peptide: a relevant marker to rule out delayed atrial fibrillation in stroke patient. J Stroke Cerebrovasc Dis. doi:10.1016/j.jstrokecerebrovasdis.2012.08.010
83. Sun JC, Davidson MJ, Lamy A, Eikelboom JW (2009) Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 374:565-76 CrossRef
84. Swedberg K, Zannad F, McMurray JJ et al (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 59:1598-603 CrossRef
85. Taylor D, Stehlik J, Edwards LB et al (2009) Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report: 2009. J Heart Lung Transplant 28:1007-022 CrossRef
86. Tricoci P, Peterson ED, Mulgund J et al (2006) Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol 98:1172-176 CrossRef
87. Vahanian A, Baumgartner H, Bax J et al (2007) Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J 28:230-68
88. Van Gelder IC, Groenveld HF, Crijns HJ et al (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:1363-373 CrossRef
89. van Walraven C, Oake N, Wells PS, Forster AJ (2007) Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromobembolic events in the elderly. Chest 131:1508-515 CrossRef
90. Verheugt FW, Steinhubl SR, Hamon M et al (2011) Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. J Am Coll Cardiol Interv 4:191-97
91. Wang TJ, Larson MG, Levy D et al (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920-925 CrossRef
92. Wang TY, Xiao L, Alexander KP et al (2008) Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 118:2139-145 CrossRef
93. Warkentin TE (2005) New approaches to the diagnosis of heparin-induced thrombocitopenia. Chest 127(2 Suppl):35S-5S CrossRef
94. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703-708
95. Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 suppl):e120S–e151S CrossRef
96. Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ (2011) Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 32:2282-289 CrossRef
97. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-015 CrossRef
98. Xian Y, Liang L, Smith EE et al (2012) Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 307:2600-608 CrossRef
99. You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians. Evidence-based Clinical Practice Guidelines. Chest 141(2 suppl):e531S–e575S CrossRef
100. Zacharski LR, Chow BK, Howes PS et al (2007) Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 297:603-10 CrossRef - 作者单位：Renato D. Lopes (1) (2)
Richard C. Becker (1)
L. Kristin Newby (1)
Eric D. Peterson (1)
Elaine M. Hylek (3)
Robert Giugliano (4)
Christopher B. Granger (1)
Kenneth W. Mahaffey (1)
Antonio C. Carvalho (2)
Otavio Berwanger (5)
Roberto R. Giraldez (6)
Gilson Soares Feitosa-Filho (7)
Marcia M. Barbosa (8)
Maria da Consolacao V. Moreira (9)
Renato A. K. Kalil (10)
Marildes Freitas (11)
Joao Carlos de Campos Guerra (12)
Marcio Vinicius Lins Barros (13)
Thiago da Rocha Rodrigues (14)
Antonio C. Lopes (2)
David A. Garcia (15)
1. Duke Clinical Research Institute, Duke University Medical Center, P.O. Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC, 27705, USA
2. Paulista School of Medicine, Federal University of S?o Paulo, S?o Paulo, SP, Brazil
3. Boston University, Boston, MA, USA
4. Brigham and Women’s Hospital, Boston, MA, USA
5. Hospital do Cora??o Research Institute, Heart Hospital, S?o Paulo, SP, Brazil
6. S?o Paulo University Medical School, S?o Paulo, SP, Brazil
7. Bahiana School of Medicine and Public Health, Salvador, BA, Brazil
8. Ecocenter, Socor Hospital, Belo Horizonte, MG, Brazil
9. Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
10. Federal University of Health Science of Porto Alegre, Porto Alegre, RS, Brazil
11. Jo?o XXIII Hospital, Belo Horizonte, MG, Brazil
12. Albert Einstein Hospital, S?o Paulo, SP, Brazil
13. Materdei Hospital, Belo Horizonte, MG, Brazil
14. Felício Rocho Hospital, Belo Horizonte, MG, Brazil
15. University of New Mexico Health Sciences Center, Albuquerque, NM, USA - ISSN：1573-742X
文摘
To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Fifth International Symposium of Thrombosis and Anticoagulation was held in Belo Horizonte, Minas Gerais, Brazil, on October 18-9, 2012. This scientific program was developed by clinicians for clinicians and was promoted by three major clinical research institutes: the Brazilian Clinical Research Institute, the Duke Clinical Research Institute of the Duke University School of Medicine, and Hospital do Cora??o Research Institute. Comprising 2?days of academic presentations and open discussion, the symposium had as its primary goal to educate, motivate, and inspire internists, cardiologists, hematologists, and other physicians by convening national and international visionaries, thought-leaders, and dedicated clinician-scientists. This paper summarizes the symposium proceedings.